The Science Hat Podcast - Season 5 Episode 5 - Navigating the pre-revenue biotech boat

Pre-revenue biotech sits at the pointy end of risk in the stock market and is not for the feint hearted, with recent global events making for a bumpy ride. For Clarity, navigating the dichotomy of building long-term assets on the back of ever reducing investment timelines has been achieved through a relentless drive to positively change the lives of people around the world through commitment to the highest standard of science and clinical development. Watch Season 5 Episode 5, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Healthcare Analyst at Canaccord Genuity, Madeleine Williams, as they discuss the dynamics of the stock market in the biotech and pharma space, investor behaviour and Clarity’s strategy of driving long-term shareholder value through hard work and dedication to improving treatment outcomes for people with cancer.